 MONROVIA, Calif.--BUSINESS WIRE--Xencor, Inc. NASDAQ: XNCR, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration FDA has granted an emergency use authorization EUA for sotrovimab previously VIR-7831, an XmAb-engineered antibody developed by Vir Biotechnology, Inc. Vir and GlaxoSmithKline plc GSK. Sotrovimab has not been ap 